National

Supreme Court Lifts Ban On Sale Of Saridon & 2 Other Drugs

ANANYA BHATNAGAR | 0
2924
| September 18 , 2018 , 14:01 IST

The Supreme Court on Monday allowed the sale of Saridon, Piriton Expectorant and Dart which were in the list of 328 fixed-dose combination (FDC) drugs banned by the Centre on the ground that there was “no therapeutic justification” for the ingredients contained in them and that they “may involve risk to human beings”.

The bench of Justice Rohinton Fali Nariman and Justice Indu Malhotra were hearing the matter concerning the ban of 328 FDC drugs which were banned for sale by the Union Health Ministry on September 7.

The bench however only allowed the sale of Saridon and two other drugs but hasn’t provided any relief to the other drugs in the banned list.

Pharma company Piramal Healthcare’s Saridon was represented by Senior Counsel Mukul Rohatgi and Advocate Siddharth Bhatnagar, along with Karanjawala and Co.’s Samarjit Pattnaik, Debmalya Banerjee, Arjun Mahajan, Puneet Relan, Aman Singh and Aviral Kapoor.

Additional Solicitor General Pinky Anand was representing the Central Government. For imposing the ban, the centre had relied on the recommendation of the drugs technical advisory board to reach a conclusion that these drugs were not safe for humans.

2016 Crackdown

Earlier in 2016, The Health Ministry had banned the distribution, sale and manufacture of around 346 FDCs

The notification was challenged before the Delhi High Court and the Supreme Court, with the latter subsequently referring the matter to the DTAB for re-assessment and re-examination.

The DTAB report stated that 328 out of the 349 FDC drugs may involve health risks to people and did not contain “therapeutic justification” for the ingredients. Therefore, the notification on September 7 this year banned the sale of FDCs like Saridon